Research programme: cancer therapeutics - Crescendo Therapeutics/TakedaAlternative Names: Humabody® drug conjugates - Crescendo Biologics/Takeda
Latest Information Update: 11 Nov 2016
At a glance
- Originator Crescendo Biologics
- Developer Crescendo Biologics; Takeda Oncology
- Class Antineoplastics; Drug conjugates; Immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer